MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Gilead Sciences Inc.

Gesloten

SectorGezondheidszorg

112.37 0.34

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

111.88

Max

114.59

Belangrijke statistieken

By Trading Economics

Inkomsten

530M

1.8B

Verkoop

29M

7.6B

K/W

Sectorgemiddelde

294.868

63.778

EPS

1.9

Dividendrendement

2.82

Winstmarge

23.557

Werknemers

17,600

EBITDA

-655M

3.1B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+3.07% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.82%

2.39%

Volgende Winsten

24 apr 2025

Volgende dividenddatum

26 jun 2025

Volgende Ex Dividend datum

13 jun 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

18B

140B

Vorige openingsprijs

112.03

Vorige sluitingsprijs

112.37

Nieuwssentiment

By Acuity

46%

54%

169 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Gilead Sciences Inc. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 feb 2025, 21:17 UTC

Winsten

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

19 dec 2024, 15:25 UTC

Belangrijke Marktbewegers

Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding

19 dec 2024, 13:38 UTC

Belangrijke Marktbewegers

Assembly Biosciences Gets $30.1 Million Equity Investment, Funding From Gilead

6 nov 2024, 22:25 UTC

Winsten

Gilead Sciences Post Higher 3Q Revenue, Raises Fiscal Year Guidance

19 mrt 2025, 14:50 UTC

Top Nieuws

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 feb 2025, 22:13 UTC

Marktinformatie
Winsten

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11 feb 2025, 21:06 UTC

Winsten

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Raises Dividend 2.6%>GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Sees 2205 Veklury Sales $1.4B>GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Sees 2025 Sales $28.2B-$28.6B >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences 4Q >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences 4Q HCV Products Sales >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences 4Q Rev Up on HIV, Oncology, Liver Disease; Partially Offset by lower sales of Veklury (Remdesivir) >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences 4Q Adj EPS $1.90 >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences 4Q Rev $7.57B >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences 4Q EPS $1.42 >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences 4Q EPS $1.42 >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences 4Q Net $1.78B >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences 4Q Rev $7.6B >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences 4Q Adj EPS $1.90 >GILD

10 jan 2025, 10:30 UTC

Top Nieuws

Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ

29 dec 2024, 08:00 UTC

Acquisities, Fusies, Overnames

Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barrons.com

19 dec 2024, 13:23 UTC

Belangrijke Marktbewegers

Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead

7 nov 2024, 16:23 UTC

Winsten

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise -- IBD

Peer Vergelijking

Prijswijziging

Gilead Sciences Inc. Prognose

Koersdoel

By TipRanks

3.07% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 115.33 USD  3.07%

Hoogste 140 USD

Laagste 90 USD

Gebaseerd op 23 Wall Street-analisten die 12-maands prijsdoelen bieden voor Gilead Sciences Inc. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

23 ratings

17

Buy

6

Hold

0

Sell

Technische score

By Trading Central

109.72 / 112.38Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

169 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.